The currently available therapies in Rheumatoid Arthritis (RA) control acute inflammation and flares but effective control of chronic inflammation remains an unmet need. Of all the late-stage assets in the current RA pipeline, olokizumab appears to be the most promising.

Click here to learn more:  Rheumatoid Arthritis